![](https://lekhim.ua/sites/default/files/cyprofloksacyn_250_mg_no10_2_0.jpg)
Ciprofloxacin
General properties
Antibacterials for systemic use. The group of fluoroquinolones.
Ciprofloxacin is indicated for treatment of the following infections: before the initiation of the therapy special attention should be paid to all available information as to the resistance to Ciprofloxacin.
Official recommendations as to the independent use of anti-bacterial agents should be considered.
Adults:
– lower respiratory tract infections caused by gram-negative bacteria;
– pneumonia;
– middle ear infections (chronic otitis media with effusion, severe course of otitis of external ear);
– exacerbations of chronic sinusitis, especially if caused by gram-negative bacteria;
– urinary tract infections;
– gonococcus urethritis and cervicitis;
– orchiepididymitis, caused by Neisseria gonorrhoeae in particular;
– inflammatory diseases of pelvic organs, caused by Neisseria gonorrhoeae in particular.
With the above mentioned infections of genital tract if Neisseria gonorrhoeae is known or suspected as a causative agent, it is especially important to obtain local information as to the resistance to Ciprofloxacin and confirm sensitivity by the laboratory analysis.
– gastro-intestinal infections (for example, traveler's diarrhea;
– intra-abdominal infections;
– skin and soft tissues infections caused by gram-negative bacteria;
– bones and joints infections;
– treatment of infections in patients with neutropenic;
– prevention of infections in patients with neutropenic;
– prevention of invasive infections caused by Neisseria meningitidis;
– pulmonary anthrax (post-exposure prophylaxis and curative therapy).
Children and adolescents
– bronchopulmonary infections in cystic fibrosis, caused by Pseudomonas aeruginosa. (in clinical trials children aged 5 to 17 years received the treatment);
– complicated urinary tract infections and pyelonephritis (in clinical trials children aged 5 to 17 years received the treatment);
– pulmonary anthrax (post-exposure prophylaxis and curative therapy).
The treatment should be initiated only by the physician experienced in treatment of cystic fibrosis and/or severe infections in children and adolescents.
Hypersensitivity to Ciprofloxacin or any other chemotherapeutic agents of quinolone group and other drug components; concomitant use with Tizanidine due to clinically significant adverse effects (arterial hypotension, sleepiness) related to increase of Tizanidine concentration in blood plasma; glucose-6-phosphate dehydrogenase deficiency.
Pharmaceutical characteristics
Round coated tablets of white or white with yellowish tint colour, biconvex. At fracture when viewed under a magnifying glass a core surrounded by one continuous layer is viewed.
Store in the original packaging at temperature not exceeding 25 °C. Keep out of reach of children.